Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-bind, placebo-controlled, dose escalation study of the safety, tolerability, and pharmacokinetics of an oral dose of LHF-535 (LHF-535-SDD) in healthy subjects

Next Previous
X
Search
Trial Profile

A double-bind, placebo-controlled, dose escalation study of the safety, tolerability, and pharmacokinetics of an oral dose of LHF-535 (LHF-535-SDD) in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LHF 535 (Primary)
  • Indications Lassa fever
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 31 Oct 2022 Results assessing Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults published in the Antimicrobial Agents and Chemotherapy
    • 06 Aug 2019 Results presented in a Kineta media release.
    • 07 May 2019 Status changed to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top